Skip to content

Replimune Group REPL Market capitalization

Market capitalization at other companies

Amgen logo
AmgenAMGN
$189.67B+13.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.68B+17.8%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$982.03M+385%
Immunome logo
ImmunomeIMNM
$2.47B+323%
CG Oncology logo
CG OncologyCGON
$5.71B+206%
Erasca, Inc. logo
Erasca, Inc.ERAS
$5.03B+1,196%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Computed from the period-end share price: $762.47M.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's market capitalization?
Replimune Group (REPL) reported market capitalization of $762.47M in Q4 2025.
How has Replimune Group's market capitalization changed year-over-year?
Replimune Group's market capitalization decreased by 18.2% year-over-year, from $931.93M to $762.47M.
What is the long-term trend for Replimune Group's market capitalization?
Over 4 years (2021 to 2025), Replimune Group's market capitalization has grown at a -14.9% compound annual growth rate (CAGR), from $1.43B to $750.89M.
What does market capitalization mean?
The total market value of the company's equity at the quarter end (share price × shares outstanding), sampled from daily market data. The latest point tracks the live price.